Unifocal 3-2 Models Unipolar & Bipolar
510(k) K792232
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK792232 | Date27 Nov 1979 | StatusActive |
Recalls
No FDA recalls found in the data synced 22 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- DXY
- Device Class
- Class III
- Regulation
- 21 CFR Part 870.3610
- Advisory Committee
- Cardiovascular
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 18 Sep 2026
The Unifocal 3-2 Models Unipolar and Bipolar is an Implantable Pacemaker Pulse-Generator, designed to regulate cardiac rhythm by delivering electrical impulses to the heart. These models are configured for single-chamber pacing, providing unipolar and bipolar pacing options to accommodate different clinical needs and patient anatomies. The device is intended for use in patients requiring artificial cardiac stimulation due to bradycardia or other conduction disorders.
This device is supplied as a reusable, non-sterile medical implant intended for surgical implantation by qualified healthcare professionals. It is classified under FDA Device Class III and holds a 510(k) clearance for substantial equivalence. The Unifocal 3-2 models are regulated under 21 CFR 870.3610 and are intended for use in controlled clinical settings, such as hospitals or specialized cardiac care facilities. No MRI safety information is specified, and storage conditions are not detailed in the provided data.
Other devices from American Pacemaker Corp.
Questions
AI-generated answers, 18 Sep 2026
What types of pacing configurations does the Unifocal 3-2 support, and how might a clinician choose between them?
The Unifocal 3-2 offers both unipolar and bipolar pacing configurations, designed for single-chamber cardiac stimulation. The choice depends on clinical needs and patient anatomy. Unipolar pacing delivers current through a single electrode and the patient’s body, while bipolar pacing uses two electrodes, which can reduce muscle stimulation and improve pacing thresholds. Clinicians may select based on factors like lead placement, patient response, and minimizing discomfort or interference.
Is this device intended for reuse, and what are the implications for clinical workflows?
The Unifocal 3-2 is explicitly described as a reusable implantable pulse-generator, not a single-use device. This means it is intended to be surgically implanted once and remain in the patient long-term, requiring no replacement for routine use. However, it is non-sterile as supplied, so it must be sterilized by the healthcare facility before implantation—a critical step in clinical workflows to ensure patient safety.
What regulatory pathway was followed for this device, and how does that affect its use in clinical settings?
The Unifocal 3-2 was cleared via the FDA’s 510(k) pathway under Traditional Review, with a decision of *Substantially Equivalent* (SESE) by the Cardiovascular (CV) Advisory Committee. This classification under FDA Device Class III and regulation 21 CFR 870.3610 indicates it is intended for high-risk medical use, requiring implantation only in controlled settings like hospitals or specialized cardiac care facilities. The clearance does not specify MRI safety, so clinicians must follow strict protocols if MRI exposure is necessary.
Are there multiple models or variations of this device, and if so, how do they differ?
The Unifocal 3-2 comes in two primary models: unipolar and bipolar. The distinction lies in their pacing circuitry—unipolar uses a single electrode pathway, while bipolar uses two electrodes to deliver the pacing impulse. Both are designed for single-chamber pacing (e.g., right atrium or ventricle) and share the same core function of regulating bradycardia or conduction disorders. No additional size or programming variations are mentioned in the data.